Tandem Diabetes Profile

7.44
USD 0.09  1.22%
95%
57%

Tandem Diabetes exotic insider transaction detected

Tandem Diabetes Care insider trading alert for general transaction of series c preferred stock by Schoemaker Kathleen K, the corporate stakeholder, on April 11, 2018. This event was filed by Tandem Diabetes Care Inc with SEC on 2013-11-13. Initial filing of beneficial ownership - SEC Form 3 [view details]   

Tandem Diabetes Summary

Tandem Diabetes Care (TNDM) is traded on NASDAQ General Markets in USA. It is located in CALIFORNIA, U.S.A and employs 574 people. Tandem Diabetes is listed under Medical Equipment category by Fama And French industry classification.The company currently falls under 'Small-Cap' category with current market capitalization of 341.95 M. Tandem Diabetes Care conducts business under Healthcare sector and is part of Medical Equipment industry. This company has 44.7 M outstanding shares of which 1.5 M shares are at this time shorted by private and institutional investors with about 1.41 trading days to cover. NEUTRAL TANDEM currently holds about 14.18 M in cash with (66.14 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.32.
Check Tandem Diabetes Probability Of Bankruptcy

Ownership Allocation (%)

Target Price Odds Analysis

Below OddsHorizonTargetAbove Odds
roughly 96.0%30 days 7.44  under 4%
Based on normal probability distribution, the odds of Tandem Diabetes to move above current price in 30 days from now is under 4% (This Tandem Diabetes Care probability density function shows the probability of Tandem Diabetes Stock to fall within a particular range of prices over 30 days) .

Top Holders

Major Institutional Holders

InstituionSecurity TypeTotal SharesValue
Ausdal Financial Partners IncCommon Shares34.6 K172 K
Creative PlanningCommon Shares26 K129 K
Alyeska Investment Group LpCall Options900 K2.1 M
View Tandem Diabetes Diagnostics

Selected Tandem Diabetes Care Income Statement Over Time

Consolidated Income    Cost of Revenue    Earning Before Interest and Taxes EBIT    

Key Fundamentals

Tandem Diabetes Against Markets

Risk Adjusted
Performance Score (0 to 100)
27 
Chance of
Financial Distress (0 to 100%)
< 38% 
Equity ratings for Tandem Diabetes Care are calculated dynamically based on Macroaxis scoring framework. Click here to learn more
Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States. Tandem Diabetes Care, Inc. was founded in 2006 and is headquartered in San Diego, California. Tandem Diabetes operates under Medical Devices classification in USA and traded on NASDAQ General Markets. It employs 574 people. more
Fama & French Medical Equipment
Medical Equipment
Fama & French Classification
NameTandem Diabetes Care
CEO and President and DirectorKim BlickenstaffView All
Analyst Consensus
Piotroski F Score
Macroaxis Advice
InstrumentUSA Stock View All
RegionNorth America
LocationCALIFORNIA, U.S.A
Business Address11045 Roselle Street
ExchangeNASDAQ General Markets
CIK Number01438133.0
CUSIP875372104
SectorHealthcare
IndustryMedical Equipment
BenchmarkDOW
Websitewww.tandemdiabetes.com
Contact Number858 366 6900
CurrencyUSD - US Dollar

Recommendations

Tandem Diabetes Analyst Recommendations
Target PriceAdvice# of Analysts
6.23Hold10Odds
Tandem Diabetes Care current and past analyst recommendations published by number of research institutions as well as average analyst consensus
Tandem Diabetes Analyst Advice  

Earnings

Tandem Diabetes Earnings Estimates
EPSEstimate Date
Quarterly Estimate-0.65March 8, 2017
Tandem Diabetes Care normalized analysts earnings estimates for actual as well as projected forward EPS values taken as an average expert opinion over time
Earnings Estimate  

Directors

Tandem Diabetes Corporate Directors
Fred Cohen Independent Director
Howard Greene Independent Director, MBA
Christopher Twomey Independent Director
Also please take a look at World Market Map. Please also try Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.